Author(s):
Narayana Goruntla, Mohammad Jaffar Sadiq, Vigneshwaran Easwaran
Email(s):
narayanagoruntla@gmail.com
DOI:
10.52711/0974-360X.2023.00327 
Address:
Narayana Goruntla1*, Mohammad Jaffar Sadiq2, Vigneshwaran Easwaran3
1Department of Pharmacy Practice, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, R Palli Cross, Chiyyedu Post, Anantapur 515721, Andhra Pradesh, India.
2Assistant Professor, Department of Clinical Pharmacology, Batterjee Medical College, Jeddah 21442, Kingdom of Saudi Arabia.
3Assistant Professor, Clinical Pharmacy Department, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2023
ABSTRACT:
Currently, there is no availability of any proven specific treatment or prevention strategy to fight against COVID-19. Convalescent plasma (CP) therapy is expected to increase survival rates in COVID-19 as in the case of emerging viral infection (SARS-CoV and MERS-CoV). To collect all the studies relevant to CP therapy in critically ill or severe COVID-19 patients and summarize the findings. The systematic review was conducted according to the PRISMA consensus statement. A systematic search was performed in PubMed, Scopus, Web of Science, and Cochrane databases on April 25, 2020. A total of six studies (28 patients) relevant to CP therapy in severe or critical COVID-19 are considered for inclusion. Two authors extracted the data about study characteristics, demographics, symptoms, co-morbidities, clinical classification of COVID-19, drug therapies, oxygen therapy, laboratory results, chest CT, neutralizing antibody titer, SARS-CoV-2 RNA load, aal outcome. The review findings revealed that CP therapy increases lymphocyte count, reduced s serum inflammatory markers (CRP, IL-6, Procalcitonin) and liver enzyme levels (AST or ALT). There was a rise in serum neutralizing antibody titers in 10 of 14 patients after CP transfusion. In 4 of 14 patients, the titer levels remain unchanged after CP transfusion. All 28 cases (100%) achieved negative to the SARS-CoV-2 RNA after CP transfusion. The convalescent plasma transfusion can improve neutralizing antibody titers and reduces the viral load in severe/critical COVID-19 patients. The review recommends a well-controlled trial design is required to give a definite statement on the safety and efficacy of convalescent plasma therapy in severe/critical COVID-19.
Cite this article:
Narayana Goruntla, Mohammad Jaffar Sadiq, Vigneshwaran Easwaran. Convalescent Plasma Transfusion in Severe or critically ill COVID 19 patients: A Rapid Systematic Review. Research Journal of Pharmacy and Technology 2023; 16(4):1992-8. doi: 10.52711/0974-360X.2023.00327
Cite(Electronic):
Narayana Goruntla, Mohammad Jaffar Sadiq, Vigneshwaran Easwaran. Convalescent Plasma Transfusion in Severe or critically ill COVID 19 patients: A Rapid Systematic Review. Research Journal of Pharmacy and Technology 2023; 16(4):1992-8. doi: 10.52711/0974-360X.2023.00327 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-4-76
REFERENCES:
1. Cucinotta D. Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomedmedica. 2020; 91(1):157-60. doi: 10.23750/abm.v91i1.9397.
2. WHO Coronavirus disease 2019(COVID-19) Situation Report – 86 (accessed on 30 Apr 2020). Url:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200415-sitrep-86-covid-19.pdf?sfvrsn=c615ea20_4
3. Cunningham AC. Goh HP. Koh D. Treatment of COVID-19: old tricks for new challenges. Critical Care. 2020;24(1):91. https://doi.org/10.1186/s13054-020-2818-6
4. Liu Y. Li J. Feng Y. Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China. Critical Care. 2020;24(1):56. doi: 10.1186/s13054-020-2786-x
5. Chen L. Xiong J. Bao L. Shi Y. Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases. 2020;20(4):398–400. doi: 10.1016/S1473-3099(20)30141-9
6. Bloch EM. Shoham S. Casadevall A. Sachais BS. Shaz B. Winters JL.Buskrick CV et al Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation 2020; 130(6):2757-65. doi:10.1172/JCI138745.
7. Momattin H. Mohammed K. Zumla A. Memish ZA. Al-Tawfiq JA. Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy. International Journal of Infectious Diseases 2013;17(10):e792–8. doi: 10.1016/j.ijid.2013.07.002
8. Ayedee N. Manocha S. Role of media (Television) in creating positive atmosphere in COVID 19 during lockdown in India. Asian Journal of Management 2020;11(4):370–8. doi: 10.5958/2321-5763.2020.00057.8
9. Moher D. Liberati A. Tetzlaff J. Altman DG. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine 2009;6(7):e1000097.https://doi.org/10.1371/journal.pmed.1000097
10. Duan K. Liu B. Li C. Zhang H. Yu T. Qu J. Zhou M et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America 2020; 117(17):9490-6. doi:10.1073/pnas.2004168117
11. Shen C. Wang Z. Zhao F. Yang Y. Li J. Yuan J. Wang F et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. The Journal of Medical Association 2020; 323(16):1582-9. doi:10.1001/jama.2020.4783
12. Zhang B. Liu S. Tan T. Huang W. Dong Y. Chen L. Chen Q et al. Treatment with Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection. Chest 2020;158(1):e9-e13. doi: 10.1016/j.chest.2020.03.039
13. Ye M. Fu D. Ren Y. Wang F. Wang D. Zhang F.Xia X et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. Journal of Medical Virology 2020;92(10):1890-1901. doi:10.1002/jmv.25882.
14. Ahn JY. Sohn Y. Lee SH. Cho Y. Hyun JH. Baek YJ. Jeong SJ et al. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. Journal of Korean Medical Science 2020;35(14):e149. doi: 10.3346/jkms.2020.35.e149
15. Shi H. Zhou C. He P. Huang S. Duan Y. Wang X. Lin K et al. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection. International Journal of Antimicrobial Agents 2020; 56(2):105974. doi: 10.1016/j.ijantimicag.2020.105974
16. Mair-Jenkins J. Saavedra-Campos M. Baillie JK. Cleary P. Khaw F-M. Lim WS. Makki S et al. The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis. The Journal of Infectious Diseases 2015;211(1):80–90. doi: 10.1093/infdis/jiu396
17. Kraft CS. Hewlett AL. Koepsell S. Winkler AM. Kratochvil CJ. Larson L. Varkey JB et al. The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. Clinical Infectious Diseases 2015;61(4):496–502. doi: 10.1093/cid/civ334
18. Hung IF. To KK. Lee CK. Lee KL, Chan K, Yan WW, Liu R et al. Convalescent Plasma Treatment Reduced Mortality in Patients with Severe Pandemic Influenza A (H1N1) 2009 Virus Infection. Clinical Infectious Diseases 2011;52(4):447–56.doi: 10.1093/cid/ciq106
19. Ng KT. Oong XY. Lim SH. Chook JB. Takebe Y. Chan YF. Chan KG et al. Viral Load and Sequence Analysis Reveal the Symptom Severity, Diversity, and Transmission Clusters of Rhinovirus Infections. Clinical Infectious Diseases 2018;67(2):261–8. doi: 10.1093/cid/ciy063
20. de Jong MD. Simmons CP. Thanh TT. Hien VM. Smith GJD. Chau TNB. Hoang DM et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nature Medicine 2006;12(10):1203–7. doi: 10.1038/nm1477
21. Shen C. Chen J. Li R. Zhang M. Wang G. Stegalkina S.Zhang L et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Science Translation Medicine 2017;9(412):eaam5752. doi: 10.1126/scitranslmed.aam5752
22. Ayedee N. Kumar A. Indian education system and growing number of online conferences: Scenario under COVID-19. Asian Journal of Management 2020;11(4):395–401. doi: 10.5958/2321-5763.2020.00060.8
23. Arunima A. Nangia R. Work from Home (WFH) and Covid-19: Encountering Ethical issues in New Normal. Asian Journal of Management 2022; 13(1):94–100. DOI: 10.52711/2321-5763.2022.00017
24. Jain RS. Jain TG. Ishikar SK. Impact of COVID-19 on changing habits and health issues of the public. Asian Journal of Management 2020;11(4):524–8.doi: 10.5958/2321-5763.2020.00077.3
25. Kumar A. Emotional intelligence can help healthcare professionals and managers: A way deal COVID-19 pandemic. Asian Journal of Management2021;12(4):353–8. doi: 10.52711/2321-5763.2021.00053
26. Vijayashree L, Srinivasa S. Covid 19 and Stress among Students. Asian Journal of Management 2021; 12(4):477–82. doi: 10.52711/2321-5763.2021.00074
27. Sarkar N. Kumar Mandal B. Paul S. Activity, Effect on Human and Salvation from effect of COVID-19. Asian Journal of Management 2021; 12(2):228–34.
28. Solanki R. Singh K. Covid-19 home confinement effects on consumer’s food consumption and eating habits. Asian Journal of Management 2021; 12(4):487–90. doi: 10.52711/2321-5763.2021.00076
29. Vankadari N. Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. International Journal of Antimicrobial Agents 2020; 56(2):105998. doi: 10.1016/j.ijantimicag.2020.105998.
30. Tahir ul Qamar M. Alqahtani SM. Alamri MA. Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. Journal of Pharmaceutical Analysis 2020; 10(4):313-9. doi: 10.1016/j.jpha.2020.03.009
31. Cao B. Wang Y. Wen D. Liu W. Wang J. Fan G.Ruan L et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine 2020;382(19):1787–99. doi: 10.1056/NEJMoa2001282
32. Ko JH. Seok H. Cho SY. Eun Ha Y. Baek JY. Kim SH.Kim YJ et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antiviral Therapy 2018;23(7):617–22. doi: 10.3851/IMP3243